Literature DB >> 24829338

Cell death-inducing DFFA-like effector b is required for hepatitis C virus entry into hepatocytes.

Xianfang Wu1, Emily M Lee1, Christy Hammack1, Jason M Robotham1, Mausumi Basu2, Jianshe Lang1, Margo A Brinton2, Hengli Tang3.   

Abstract

UNLABELLED: The molecular mechanism of the hepatic tropism of hepatitis C virus (HCV) remains incompletely defined. In vitro hepatic differentiation of pluripotent stem cells produces hepatocyte-like cells (HLCs) permissive for HCV infection, providing an opportunity for studying liver development and host determinants of HCV susceptibility. We previously identified the transition stage of HCV permissiveness and now investigate whether a host protein whose expression is induced during this transition stage is important for HCV infection. We suppressed the expression of a liver-specific protein, cell death-inducing DFFA-like effector b (CIDEB), and performed hepatocyte function and HCV infection assays. We also used a variety of cell-based assays to dissect the specific step of the HCV life cycle that potentially requires CIDEB function. We found CIDEB to be an essential cofactor for HCV entry into hepatocytes. Genetic interference with CIDEB in stem cells followed by hepatic differentiation leads to HLCs that are refractory to HCV infection, and infection time course experiments revealed that CIDEB functions in a late step of HCV entry, possibly to facilitate membrane fusion. The role of CIDEB in mediating HCV entry is distinct from those of the well-established receptors, as it is not required for HCV pseudoparticle entry. Finally, HCV infection effectively downregulates CIDEB protein through a posttranscriptional mechanism. IMPORTANCE: This study identifies a hepatitis C virus (HCV) entry cofactor that is required for HCV infection of hepatocytes and potentially facilitates membrane fusion between viral and host membranes. CIDEB and its interaction with HCV may open up new avenues of investigation of lipid droplets and viral entry.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24829338      PMCID: PMC4135929          DOI: 10.1128/JVI.00081-14

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  66 in total

1.  EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy.

Authors:  Joachim Lupberger; Mirjam B Zeisel; Fei Xiao; Christine Thumann; Isabel Fofana; Laetitia Zona; Christopher Davis; Christopher J Mee; Marine Turek; Sebastian Gorke; Cathy Royer; Benoit Fischer; Muhammad N Zahid; Dimitri Lavillette; Judith Fresquet; François-Loïc Cosset; S Michael Rothenberg; Thomas Pietschmann; Arvind H Patel; Patrick Pessaux; Michel Doffoël; Wolfgang Raffelsberger; Olivier Poch; Jane A McKeating; Laurent Brino; Thomas F Baumert
Journal:  Nat Med       Date:  2011-04-24       Impact factor: 53.440

2.  Targeting DNA double-strand breaks with TAL effector nucleases.

Authors:  Michelle Christian; Tomas Cermak; Erin L Doyle; Clarice Schmidt; Feng Zhang; Aaron Hummel; Adam J Bogdanove; Daniel F Voytas
Journal:  Genetics       Date:  2010-07-26       Impact factor: 4.562

3.  De novo-engineered transcription activator-like effector (TALE) hybrid nuclease with novel DNA binding specificity creates double-strand breaks.

Authors:  Magdy M Mahfouz; Lixin Li; Md Shamimuzzaman; Anjar Wibowo; Xiaoyun Fang; Jian-Kang Zhu
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-24       Impact factor: 11.205

4.  CIDE, a novel family of cell death activators with homology to the 45 kDa subunit of the DNA fragmentation factor.

Authors:  N Inohara; T Koseki; S Chen; X Wu; G Núñez
Journal:  EMBO J       Date:  1998-05-01       Impact factor: 11.598

5.  A TALE nuclease architecture for efficient genome editing.

Authors:  Jeffrey C Miller; Siyuan Tan; Guijuan Qiao; Kyle A Barlow; Jianbin Wang; Danny F Xia; Xiangdong Meng; David E Paschon; Elo Leung; Sarah J Hinkley; Gladys P Dulay; Kevin L Hua; Irina Ankoudinova; Gregory J Cost; Fyodor D Urnov; H Steve Zhang; Michael C Holmes; Lei Zhang; Philip D Gregory; Edward J Rebar
Journal:  Nat Biotechnol       Date:  2010-12-22       Impact factor: 54.908

6.  CD81-dependent binding of hepatitis C virus E1E2 heterodimers.

Authors:  Laurence Cocquerel; Chiung-Chi Kuo; Jean Dubuisson; Shoshana Levy
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

7.  Binding of hepatitis C virus to CD81.

Authors:  P Pileri; Y Uematsu; S Campagnoli; G Galli; F Falugi; R Petracca; A J Weiner; M Houghton; D Rosa; G Grandi; S Abrignani
Journal:  Science       Date:  1998-10-30       Impact factor: 47.728

8.  Hepatitis C virus subgenomic replicons in the human embryonic kidney 293 cell line.

Authors:  Samir Ali; Charles Pellerin; Daniel Lamarre; George Kukolj
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

9.  TAL nucleases (TALNs): hybrid proteins composed of TAL effectors and FokI DNA-cleavage domain.

Authors:  Ting Li; Sheng Huang; Wen Zhi Jiang; David Wright; Martin H Spalding; Donald P Weeks; Bing Yang
Journal:  Nucleic Acids Res       Date:  2010-08-10       Impact factor: 16.971

10.  Efficient construction of sequence-specific TAL effectors for modulating mammalian transcription.

Authors:  Feng Zhang; Le Cong; Simona Lodato; Sriram Kosuri; George M Church; Paola Arlotta
Journal:  Nat Biotechnol       Date:  2011-01-19       Impact factor: 54.908

View more
  20 in total

1.  Attachment and Postattachment Receptors Important for Hepatitis C Virus Infection and Cell-to-Cell Transmission.

Authors:  Huahao Fan; Luhua Qiao; Kyung-Don Kang; Junfen Fan; Wensheng Wei; Guangxiang Luo
Journal:  J Virol       Date:  2017-06-09       Impact factor: 5.103

2.  Mice Expressing Minimally Humanized CD81 and Occludin Genes Support Hepatitis C Virus Uptake In Vivo.

Authors:  Qiang Ding; Markus von Schaewen; Gabriela Hrebikova; Brigitte Heller; Lisa Sandmann; Mario Plaas; Alexander Ploss
Journal:  J Virol       Date:  2017-01-31       Impact factor: 5.103

Review 3.  Pathophysiology of lipid droplet proteins in liver diseases.

Authors:  Rotonya M Carr; Rexford S Ahima
Journal:  Exp Cell Res       Date:  2015-10-26       Impact factor: 3.905

Review 4.  Hepatitis C virus and antiviral innate immunity: who wins at tug-of-war?

Authors:  Da-Rong Yang; Hai-Zhen Zhu
Journal:  World J Gastroenterol       Date:  2015-04-07       Impact factor: 5.742

5.  The missing pieces of the HCV entry puzzle.

Authors:  Sarah C Ogden; Hengli Tang
Journal:  Future Virol       Date:  2015       Impact factor: 1.831

Review 6.  The impact of hepatitis C virus entry on viral tropism.

Authors:  Qiang Ding; Markus von Schaewen; Alexander Ploss
Journal:  Cell Host Microbe       Date:  2014-11-12       Impact factor: 21.023

7.  TIM-1 Promotes Hepatitis C Virus Cell Attachment and Infection.

Authors:  Jing Wang; Luhua Qiao; Zhouhua Hou; Guangxiang Luo
Journal:  J Virol       Date:  2017-01-03       Impact factor: 5.103

Review 8.  Recent advances in hepatocellular carcinoma therapy.

Authors:  Rinku Dutta; Ram I Mahato
Journal:  Pharmacol Ther       Date:  2017-02-05       Impact factor: 12.310

Review 9.  Host restriction factors for hepatitis C virus.

Authors:  Li-Ya Zhou; Lei-Liang Zhang
Journal:  World J Gastroenterol       Date:  2016-01-28       Impact factor: 5.742

10.  Single Particle Imaging of Polarized Hepatoma Organoids upon Hepatitis C Virus Infection Reveals an Ordered and Sequential Entry Process.

Authors:  Yasmine Baktash; Anisha Madhav; Kelly E Coller; Glenn Randall
Journal:  Cell Host Microbe       Date:  2018-03-14       Impact factor: 21.023

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.